Updates in HCM Management: An Expert Interpretation of the ESC Cardiomyopathy Guidelines 2023
Live from ESC 2023 in Amsterdam, this broadcast will bring together the chairpersons of the latest ESC Guidelines on Cardiomyopathy, released on Sunday 27 August 2023.
Prof Elena Arbelo (Hospital Clinic, Barcelona, ES) and Prof Juan Pablo Kaski (University College London, UK) will provide definitive commentary on the guideline updates – including what's new in hypertrophic cardiomyopathy (HCM), what are the treatment recommendations for obstructive hypertrophic cardiomyopathy (oHCM), and how the new guidelines affect the current management paradigm.
The broadcast is curated to focus on the implications for healthcare practitioners. The guideline authors will consider how practices can accommodate novel agents for oHCM, the responsibilities for prescribing therapies and the impact on existing treatment strategies.
Fully interactive, this session is designed to support health practitioners understand the latest guideline recommendations and ensure their effective implementation.
This broadcast will be of particular educational value for Cardiologists, Heart Failure Specialists, Electrophysiologists and Cardiac Surgeons. Additionally, any HCPs who specialise in treating HCM or could be considered as part of the wider care team in the identification and referral to specialist assessment globally will find this of interest.
SUBMIT YOUR QUESTIONS: Do you have a question on the new guidelines? Do you have a dilemma in HCM and want to know how the latest guidance could impact it? Profs Arbelo and Kaski invite you to submit your questions below, which will be answered live during the broadcast's experts-on-the-spot segment.
REGISTER NOW to attend this important educational broadcast.
This broadcast is supported by an unrestricted educational grant from Bristol Myers Squibb.
What’s New for HCM?
• Overview of major updates from previous guidance (diagnosis, interdisciplinary care, treatment, monitoring practice)
• Focus on treatment recommendations in oHCM
• How this changes the current management paradigm for oHCM
• What can be expected in the future for oHCM and non-obstructive HCM
Practical Implications for Practitioners
• How practices can accommodate novel agents for oHCM
• Who will be responsible for prescribing therapies?
• Impact on existing treatment strategies
• Symptom control vs disease modifying therapy
• Best practices
• Live audience questions and pre-submitted clinical questions
- Recall guideline updates relevant to the use of disease modifying agents in hypertrophic cardiomyopathy
- Identify patients who, according to guidelines, may benefit from emerging disease modifying therapies prior to septal ablation therapy or being managed by symptom control alone
- Discuss long-term management strategies for patients receiving myosin inhibitor therapy
- Heart Failure Specialists
- Cardiac Surgeons
- HCPs who specialise in treating HCM
Prof Elena Arbelo is a Cardiac Electrophysiologist at Hospital Clínic of Barcelona, Barcelona, Spain, where she serves as Coordinator of the Cardiac Genetic Diseases and Sudden Arrhythmic Death Unit.
She is a Clinical Professor at the University of Barcelona and a researcher at the Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS). Prof Arbelo is a member of several committees of the European Society of Cardiology (ESC), the European Heart Rhythm Association (EHRA), and the Heart Rhythm Society (HRS).
Prof Arbelo is a committee member for several large-scale European Registries to gather data on atrial fibrillation and guideline implementation. She serves as a member of the Working Group on Atrial Fibrillation of the International Consortium for Health Outcomes Measurement (ICHOM).
Prof Arbelo is an editorial board member of Arrhythmia & Electrophysiology Review journal.
Prof Kaski is an Associate Professor at the Centre for Inherited Cardiovascular Diseases, UCL, London, UK. He is also a consultant paedriatric cardiologist, and Director of the Inherited Cardiovascular Diseases Unit at the Great Ormond Street Hospital for Children NHS Trust, UK.
For his work on the genetic basis of pre-adolescent hypertrophic cardiomyopathy, Prof Kaski was awarded the Young Investigator Award by the European Society of Cardiology (ESC) in 2008.
Prof Kaski's research interests include cardiomyopathies, inherited arrhythmias, aortopathy syndromes and rare cardiovascular genetic diseases. His main focuses include heart muscle disease, ion channel diseases, sudden cardiac death and Marfan syndrome.
Prof Juan-Pablo Kaski is on the Editorial Board of European Cardiology Review, in addition to other leading journals.